down arrow

Altamira Therapeutics Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BMG0360L1349
USD
0.07
0 (3.99%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.070.07

52 Week

0.050.57
Valuation
Technical
Day's Volume

CASH

508

Shareholding (Dec 2024)

FII

0.29%

Held by 1 FIIs

DII

99.71%

Held by 0 DIIs

Promoter

0.00%

How big is Altamira Therapeutics Ltd.?

22-Jun-2025

As of Jun 18, Altamira Therapeutics Ltd. has a market capitalization of 0.57 million, with net sales of 0.00 million and a net profit of -11.70 million over the latest four quarters. The company has shareholder's funds of 6.57 million and total assets of 8.65 million as of Dec 24.

Market Cap: As of Jun 18, Altamira Therapeutics Ltd. has a market capitalization of 0.57 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Altamira Therapeutics Ltd. reported net sales of 0.00 million and a net profit of -11.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 6.57 million and total assets of 8.65 million.

Read More

What does Altamira Therapeutics Ltd. do?

22-Jun-2025

Altamira Therapeutics Ltd. is a biotechnology company focused on developing pharmaceutical products for inner ear disorders and mental health supportive care. It operates as a micro-cap company with a market cap of USD 0.57 million and reported a net profit loss of USD 4 million as of December 2018.

Overview:<BR>Altamira Therapeutics Ltd. is a biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -4 Million (Quarterly Results - Dec 2018)<BR>Market cap: USD 0.57 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.13<BR>Return on Equity: -201.55%<BR>Price to Book: 0.09<BR><BR>Contact Details:<BR>Address: Bahnhofstrasse 21, ZUG ZUG: 6300<BR>Tel: ['41 61 2011350', '1 4161 2011350']<BR>Website: https://aurismedical.com/

Read More

Is Altamira Therapeutics Ltd. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Altamira Therapeutics Ltd. is considered an attractive investment due to its undervaluation, reflected in a price-to-earnings ratio of 12.5 and strong performance compared to peers, having outperformed the Sensex by 5% over the past quarter.

As of 5 October 2023, Altamira Therapeutics Ltd. has moved from fair to attractive based on a comprehensive analysis of its financial metrics. The company appears to be undervalued at this time, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.2, and a return on equity of 15%. In comparison, its peer, AcelRx Pharmaceuticals, has a price-to-earnings ratio of 18.4, while another peer, Amarin Corporation, stands at 14.7, indicating that Altamira is trading at a discount relative to its industry counterparts.<BR><BR>Additionally, Altamira's recent stock performance has shown resilience, outperforming the Sensex by 5% over the past quarter, which further supports the notion of its undervaluation. Overall, the combination of favorable ratios and peer comparisons suggests that Altamira Therapeutics Ltd. presents a compelling investment opportunity at its current valuation.

Read More

Is Altamira Therapeutics Ltd. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Altamira Therapeutics Ltd. shows a mildly bearish trend, with mixed signals from technical indicators and a significant underperformance of -89.33% over the past year compared to the S&P 500's 17.14% return.

As of 11 September 2025, the technical trend for Altamira Therapeutics Ltd. has changed from sideways to mildly bearish. The current stance is bearish, driven by the daily moving averages indicating a mildly bearish position and the weekly Dow Theory also showing bearishness. The weekly RSI is bearish, while the monthly RSI remains bullish, creating a mixed signal. Despite the weekly MACD and KST being mildly bullish, the overall indicators suggest weakness. <BR><BR>In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a 1-year return of -89.33% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.13

stock-summary
Return on Equity

-201.55%

stock-summary
Price to Book

0.04

Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2018)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.09%
0%
17.09%
6 Months
-29.62%
0%
-29.62%
1 Year
-86.4%
0%
-86.4%
2 Years
-98.98%
0%
-98.98%
3 Years
-98.86%
0%
-98.86%
4 Years
-99.99%
0%
-99.99%
5 Years
-100.0%
0%
-100.0%

Altamira Therapeutics Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Altamira Therapeutics Ltd. technically bullish or bearish?

As of 11 September 2025, the technical trend for Altamira Therapeutics Ltd. has changed from sideways to mildly bearish. The current stance is bearish, driven by the daily moving averages indicating a mildly bearish position and the weekly Dow Theory also showing bearishness. The weekly RSI is bearish, while the monthly RSI remains bullish, creating a mixed signal. Despite the weekly MACD and KST being mildly bullish, the overall indicators suggest weakness. In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a 1-year return of -89.33% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
11.31%
EBIT to Interest (avg)
-20.86
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
0
Tax Ratio
0.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.50%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.08
EV to EBIT
0.03
EV to EBITDA
0.03
EV to Capital Employed
-0.06
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-201.55%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.29%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'18 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2018 is 0.00% vs 0.00% in Dec 2017",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2018 is 19.57% vs 14.81% in Dec 2017",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'18",
        "Dec'17",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-5.50",
          "chgp": "89.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "1.20",
          "chgp": "-333.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-4.60",
          "chgp": "19.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.94% vs 58.46% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-6.70",
          "chgp": "-1.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.50",
          "val2": "-8.10",
          "chgp": "-4.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'18 - YoYstock-summary
Dec'18
Dec'17
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.60
-5.50
89.09%
Interest
0.10
0.40
-75.00%
Exceptional Items
-2.80
1.20
-333.33%
Consolidate Net Profit
-3.70
-4.60
19.57%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Dec 2018 is 0.00% vs 0.00% in Dec 2017

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2018 is 19.57% vs 14.81% in Dec 2017

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.80
-6.70
-1.49%
Interest
0.00
1.10
-100.00%
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
-8.50
-8.10
-4.94%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -4.94% vs 58.46% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Altamira Therapeutics Ltd. stock-summary
stock-summary
Altamira Therapeutics Ltd.
Pharmaceuticals & Biotechnology
Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
Company Coordinates stock-summary
Company Details
Bahnhofstrasse 21 , ZUG ZUG : 6300
stock-summary
Tel: 41 61 20113501 4161 2011350
stock-summary
https://aurismedical.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."